42Z.F REVOLUTION MED. DL-0001

Healthcare Biotechnology Frankfurt Exchange
163.10 EUR
Close of Nov 11, 2026
54.50 192.65
Market cap
EUR 35.3B
P/E
-
P/B
17.94x
ROE
-83.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 42Z.F undervalued?

Graham number

The Graham number of REVOLUTION MED. DL-0001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

REVOLUTION MED. DL-0001 fundamental analysis

No fundamental analysis for REVOLUTION MED. DL-0001 yet.

REVOLUTION MED. DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About REVOLUTION MED. DL-0001

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-a…

Full company profile